Concord Biotech

Why is Concord Biotech Ltd falling/rising?

As of 29-Jun, Concord Biotech Ltd's stock price is declining, currently at 1,262.20, with a 30.78% drop over the past year and a recent profit decline of 28.02%. The company's poor long-term growth and high valuation contribute to the negative market sentiment.

As of 29-Jun, Concord Biotech Ltd's stock price is falling, currently at 1,262.20, reflecting a decrease of 21.8 points or 1.7%. The stock has been on a downward trend, having underperformed its sector by 2.73% today and experiencing a consecutive decline over the last four days, resulting in a total drop of 5.81% during this period. <BR><BR>In terms of performance over various time frames, the stock has shown a significant decline of 30.78% over the past year, which is considerably worse than the broader market, as the BSE500 index only fell by 2.97% in the same timeframe. Additionally, the company's net sales growth has been modest at an annual rate of 7.33% over the last five years, and its operating profit growth is even lower at 0.42%. <BR><BR>The latest financial results indicate a decline in profit after tax (PAT) by 28.02% over the last six months, which further contributes to the negative sentiment surrounding the stock. Although the company boasts a high return on equity (ROE) of 17.91% and is net-debt free, the valuation appears expensive with a price-to-book ratio of 6.5, especially given the flat results reported in March 2026 and the significant profit drop of 29.1% over the past year. <BR><BR>Overall, these factors combined—poor long-term growth, declining profits, and underperformance relative to the market—are contributing to the falling stock price of Concord Biotech Ltd.

Which are the latest news on Concord Biotech?

Should I buy, sell or hold Concord Biotech Ltd?

What does Concord Biotech do?

Concord Biotech Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 326 Cr and a net profit of 89 Cr for March 2026. The company has a market cap of INR 13,671 Cr and key metrics include a P/E of 53.00 and a dividend yield of 0.84%.

Overview: <BR>Concord Biotech Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History: <BR>Concord Biotech Limited was originally incorporated as Servomed Pharmaceuticals Private Limited in 1984. The company changed its name to Concord Biotech Limited in 2001, transitioning to a Public Company. The latest quarterly results report net sales and profit for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 326 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 89 Cr (Quarterly Results - Mar 2026) <BR>Market cap: INR 13,671 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 53.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.84% <BR>Debt Equity: -0.20 <BR>Return on Equity: 13.06% <BR>Price to Book: 6.60 <BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

How big is Concord Biotech?

As of 10th June, Concord Biotech Ltd has a market capitalization of 13,671.00 Cr, with recent net sales of 1,054.90 Cr and a net profit of 260.91 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Concord Biotech Ltd has a market capitalization of 13,671.00 Cr, classifying it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,054.90 Cr, while the sum of Net Profit for the same period is 260.91 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 1,812.72 Cr, and Total Assets amount to 2,034.25 Cr.

Who are in the management team of Concord Biotech?

The management team of Concord Biotech includes Chairman Sudhir Jairam Vaid, Joint Managing Director & CEO Ankur Vaid, and several independent and non-executive directors, along with Vice President & Company Secretary S Prakash, who collectively guide the company's strategic direction and operations.

The management team of Concord Biotech includes the following key individuals:<BR><BR>1. **Sudhir Jairam Vaid** - Chairman & Managing Director<BR>2. **Ankur Vaid** - Joint Managing Director & CEO<BR>3. **Ravi Kapoor** - Non Executive Director<BR>4. **Rajiv Agarwal** - Nominee<BR>5. **Utpal Sheth** - Nominee<BR>6. **Amit Varma** - Nominee<BR>7. **Bharti Khanna** - Independent Director<BR>8. **Anil Katyal** - Independent Director<BR>9. **Amitabh Thakore** - Independent Director<BR>10. **Arvind Agarwal** - Independent Director<BR>11. **Jayaram Easwaran** - Independent Director<BR>12. **Mandayam Chakravarthy Sriraman** - Independent Director<BR>13. **S Prakash** - Vice President & Company Secretary<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Who are the peers of the Concord Biotech?

Concord Biotech's peers include Caplin Point Lab, Cohance Life, Natco Pharma, Jubilant Pharmo, Alembic Pharma, Alivus Life, Marksans Pharma, Shilpa Medicare, and Viyash Scientifi. Most peers exhibit below-average growth and varying management risks, with Shilpa Medicare showing the highest 1-year return at 15.43% and Cohance Life the lowest at -57.78%.

Peers: The peers of Concord Biotech are Caplin Point Lab, Cohance Life, Natco Pharma, Jubilant Pharmo, Alembic Pharma, Alivus Life, Marksans Pharma, Shilpa Medicare, and Viyash Scientifi.<BR><BR>Quality Snapshot: Excellent management risk is observed at Caplin Point Lab, Natco Pharma, Alembic Pharma, Concord Biotech, Alivus Life, and Marksans Pharma, while Average management risk is found at Cohance Life and Viyash Scientifi. Below Average management risk is noted at Shilpa Medicare. All peers exhibit Below Average growth, except for Concord Biotech, which shares this rating with Cohance Life, Natco Pharma, Jubilant Pharmo, Alembic Pharma, Alivus Life, Marksans Pharma, and Viyash Scientifi. Excellent capital structure is seen at Caplin Point Lab, Cohance Life, Natco Pharma, Alembic Pharma, Concord Biotech, Alivus Life, and Marksans Pharma, while Average capital structure is noted at Jubilant Pharmo and Below Average at Shilpa Medicare and Viyash Scientifi.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Shilpa Medicare at 15.43%, while Cohance Life has the lowest at -57.78%. Concord Biotech's 1-year return is -37.64%, which is higher than Cohance Life but lower than Shilpa Medicare. Additionally, Cohance Life, Natco Pharma, Jubilant Pharmo, Alembic Pharma, and Shilpa Medicare have negative six-month returns.

Are Concord Biotech Ltd latest results good or bad?

Concord Biotech Ltd's latest results show mixed performance: while revenue grew by 12.43% quarter-on-quarter, net profit declined by 15.07% year-on-year, and operating margins fell to 35.64%. Overall, the results indicate underlying operational challenges despite some positive revenue growth.

Concord Biotech Ltd's latest results present a mixed picture. On one hand, the company achieved a revenue growth of 12.43% quarter-on-quarter, reaching ₹277.77 crores, which is a positive sign. Year-on-year, revenue also increased by 13.74%. However, profitability metrics tell a different story. The net profit for the quarter was ₹64.48 crores, reflecting a modest increase of 1.42% compared to the previous quarter but a significant decline of 15.07% year-on-year.<BR><BR>Operating margins have come under pressure, dropping to 35.64% from 40.11% a year earlier, indicating ongoing cost challenges. This margin compression raises concerns about the company's ability to maintain profitability in the face of rising costs. Additionally, the company has underperformed compared to the broader pharmaceutical sector, which has seen positive returns, while Concord Biotech's stock has declined significantly over the past year.<BR><BR>Overall, while there are some positive indicators in terms of revenue growth, the decline in profitability and margins suggests that the results are not entirely favorable, pointing to underlying operational challenges that need to be addressed.

How has been the historical performance of Concord Biotech?

Concord Biotech has shown consistent growth over the past four years, with net sales increasing from 712.93 Cr in Mar'22 to 1,200.09 Cr in Mar'25, and profit after tax rising from 178.57 Cr to 372.96 Cr. However, cash flow management faced challenges, with a decline in operating cash flow and a net cash outflow in the latest fiscal year.

Answer:<BR>The historical performance of Concord Biotech shows a consistent growth trajectory in key financial metrics over the past four years.<BR><BR>Breakdown:<BR>Concord Biotech's net sales have increased from 712.93 Cr in Mar'22 to 1,200.09 Cr in Mar'25, reflecting a strong upward trend. Total operating income followed a similar pattern, rising from 712.93 Cr to 1,200.09 Cr during the same period. The company's total expenditure, excluding depreciation, also grew from 439.66 Cr in Mar'22 to 693.76 Cr in Mar'25, indicating increased operational costs. Operating profit (PBDIT) saw a significant rise from 296.69 Cr in Mar'22 to 550.78 Cr in Mar'25, showcasing improved profitability. Profit before tax increased from 241.16 Cr to 495.87 Cr, while profit after tax rose from 178.57 Cr to 372.96 Cr, demonstrating effective cost management and revenue generation. The earnings per share (EPS) improved from 16.72 in Mar'22 to 35.53 in Mar'25, reflecting enhanced shareholder value. On the balance sheet, total assets grew from 1,312.79 Cr to 2,034.25 Cr, and total liabilities increased from 1,312.79 Cr to 2,034.25 Cr, indicating a robust growth in the company's financial position. Cash flow from operating activities showed a slight decline from 265.00 Cr in Mar'24 to 244.00 Cr in Mar'25, while net cash outflow was recorded at -14.00 Cr in Mar'25, down from a positive inflow of 11.00 Cr in Mar'24. Overall, Concord Biotech has demonstrated strong growth in sales, profits, and asset base, although cash flow management appears to have faced some challenges in the latest fiscal year.

Is Concord Biotech technically bullish or bearish?

As of October 7, 2025, Concord Biotech's trend is mildly bearish due to bearish signals from the MACD and Bollinger Bands, despite some underlying buying pressure indicated by the On-Balance Volume.

As of 7 October 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the weekly MACD and Bollinger Bands indicating bearish signals. The daily moving averages also reflect a bearish outlook. However, the On-Balance Volume (OBV) shows bullish strength on both weekly and monthly time frames, suggesting some underlying buying pressure. Overall, the lack of strong bullish indicators and the presence of bearish signals in multiple areas indicate a cautious stance on Concord Biotech.

Who are the top shareholders of the Concord Biotech?

The top shareholders of Concord Biotech include Sudhir Vaid, who holds 28.84%, followed by 22 mutual funds with 5.16%, 92 foreign institutional investors with 9.35%, and the Aryaman Jhunjhunwala discretionary trust at 8.03%. Individual investors own a total of 6.94% of the company.

The top shareholders of Concord Biotech include the promoters, who hold the majority of the shares. The promoter with the highest holding is Sudhir Vaid, owning 28.84% of the company. Additionally, there are 22 mutual funds that collectively hold 5.16% of the shares, while 92 foreign institutional investors (FIIs) hold 9.35%. The highest public shareholder is the Aryaman Jhunjhunwala discretionary trust, which holds 8.03%. Individual investors collectively own 6.94% of the company.

Is Concord Biotech overvalued or undervalued?

As of August 21, 2023, Concord Biotech is considered very expensive and overvalued, with high valuation ratios significantly exceeding its peers, despite a strong 38.84% return over the past year.

As of 21 August 2023, Concord Biotech's valuation grade has moved from does not qualify to very expensive. The company is currently overvalued based on its high valuation ratios, including a PE ratio of 54.06, an EV to EBITDA of 39.12, and a PEG ratio of 2.41. These figures significantly exceed those of its peers, such as Sun Pharmaceutical Industries Ltd. with a PE of 35.25 and Divi's Laboratories Ltd. with an EV to EBITDA of 57.35.<BR><BR>In comparison to its peers, Concord Biotech's financial metrics suggest it is trading at a premium, indicating a lack of justification for its current price. While the company has shown strong returns over the past year, outperforming the Sensex with a 38.84% return compared to the Sensex's 7.53%, the overall valuation still reflects an overvalued status in the current market landscape.

When is the next results date for Concord Biotech?

No Upcoming Board Meetings

Has Concord Biotech declared dividend?

Yes, Concord Biotech Ltd has declared an 875% dividend, amounting to ₹8.75 per share, with an ex-date of June 21, 2024. While the 1-year total return is 33.35%, the recent 6-month return is -10.59%.

Yes, Concord Biotech Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 875%<BR>- Amount per share: 8.75<BR>- Ex-date: Jun-21-2024<BR><BR>Dividend Yield: 0.47%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -10.59%, the dividend return was 0%, resulting in a total return of -10.59%.<BR><BR>For the 1-year period, the price return was 32.75%, the dividend return was 0.60%, leading to a total return of 33.35%.<BR><BR>Over the 2-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the 3-year period, both the price return and dividend return were 0%, resulting in a total return of 0.0%.<BR><BR>For the 4-year period, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>In the 5-year period, the price return was 0% and the dividend return was also 0%, resulting in a total return of 0.0%.<BR><BR>Overall, while Concord Biotech has declared a significant dividend, the total returns over various periods show mixed performance, with a notable positive return in the 1-year period but negative returns in the recent 6-month period.